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ABSTRACT
Prompt uptake of antiretroviral treatment (ART) is essential to ensure the success of universal test
and treat (UTT) strategies to prevent HIV transmission in high-prevalence settings. We describe ART
initiation rates and associated factors within an ongoing UTT cluster-randomized trial in rural South
Africa. HIV-positive individuals were offered immediate ART in the intervention arm vs. national
guidelines recommended initiation (CD4≤350 cells/mm3) in the control arm. We used data
collected up to July 2015 among the ART-eligible individuals linked to TasP clinics before
January 2015. ART initiation rates at one (M1), three (M3) and six months (M6) from baseline visit
were described by cluster and CD4 count strata (cells/mm3) and other eligibility criteria: ≤100;
100–200; 200–350; CD4>350 with WHO stage 3/4 or pregnancy; CD4>350 without WHO stage 3/
4 or pregnancy. A Cox model accounting for covariate effect changes over time was used to
assess factors associated with ART initiation. The 514 participants had a median [interquartile
range] follow-up duration of 1.08 [0.69; 2.07] months until ART initiation or last visit. ART
initiation rates at M1 varied substantially (36.9% in the group CD4>350 without WHO stage 3/4
or pregnancy, and 55.2–71.8% in the three groups with CD4≤350) but less at M6 (from 85.3% in
the first group to 96.1–98.3% in the three other groups). Factors associated with lower ART
initiation at M1 were a higher CD4 count and attending clinics with both high patient load and
higher cluster HIV prevalence. After M1, having a regular partner was the only factor associated
with higher likelihood of ART initiation. These findings suggest good ART uptake within a UTT
setting, even among individuals with high CD4 count. However, inadequate staffing and
healthcare professional practices could result in prioritizing ART initiation in patients with the
lowest CD4 counts.
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Introduction
There is substantial evidence that antiretroviral treat-
ment (ART) provides strong health benefits at both indi-
vidual and population levels. ART improves morbidity
and mortality, including in HIV-positive individuals
with asymptomatic infection and high CD4 counts
(INSIGHT START Study Group et al., 2015; TEM-
PRANO ANRS 12136 Study Group et al., 2015). ART
at higher CD4 counts has also been shown to reduce
HIV transmission to uninfected sexual partners by main-
taining viral load at undetectable level (Cohen et al.,
2011; Donnell et al., 2010). Furthermore, a recent study
demonstrated that increased ART coverage at lower
CD4 counts was associated with a significant decrease
in HIV incidence at the population level (Tanser, Bär-
nighausen, Grapsa, Zaidi, & Newell, 2013). This inverse
relationship between ART coverage and HIV incidence
together with the clear clinical benefits of extended
ART use are the principles underlying the adoption of
© 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
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the universal test and treat (UTT) strategy to prevent
HIV transmission in high-prevalence settings.
However, challenges in the HIV-care cascade are well
documented (Iwuji et al., 2015) with low HIV test uptake
as well as poor linkage to care and delay in initiating
ART amongst eligible individuals in care often cited as
barriers to achieving these benefits (Fox et al., 2014;
Kranzer, Govindasamy, Ford, Johnston, & Lawn, 2012;
McNairy et al., 2015; Musheke et al., 2013).
In recent years, the CD4 criterion for ART initiation
evolved towards earlier initiation in WHO’s recommen-
dations and subsequent national recommendations:
≤350 cells/mm3 in 2010, ≤500 cells/mm3 in 2013,
regardless of CD4 count in 2015 (WHO, 2010, 2013,
2015), based on evidence from clinical trials (TEM-
PRANO ANRS 12136 Study Group et al., 2015). How-
ever, there is little evidence from “real life” settings on
the acceptability and uptake of early ART in mostly
asymptomatic individuals in care who have a CD4 >
350 count cells/mm3.
The UTT TasP trial which is ongoing in rural South
Africa provides the opportunity to study this issue. We
aimed to describe the uptake of ART according to CD4
count strata and associated factors among HIV-positive
individuals who linked to care after home-based HIV
testing.
Methods
Study setting and design
The ANRS 12249 TasP trial is a cluster-randomized trial
implemented in theHlabisa sub-district, located innorthern
KwaZulu-Natal in South-Africa, which is a largely rural area
with scatteredhomesteads andanestimatedHIVprevalence
of 29% (Zaidi, Grapsa, Tanser, Newell, & Bärnighausen,
2013). The protocol of the TasP trial is described in detail
elsewhere (Iwuji et al., 2013; Orne-Gliemann et al., 2015).
In summary, the trial was implemented in 22 geographic
clusters over time: 4 clusters opened in March 2012, 6 clus-
ters opened in January 2013 and 12 additional clusters
opened in July 2014. Each cluster is composed of an average
population of about 1000 residents≥16 years old. Themain
hypothesis of the TasP trial is that HIV testing of all adult
members of a community, followed by immediate ART
initiation of all, or nearly all, HIV-infected participants
regardless of immunological or clinical staging, will prevent
onward transmission and reduce HIV incidence in this
population.Only individuals aged16 years or older and resi-
dent in the trial clusters are eligible for trial participation.
The UTT strategy being tested in the TasP trial has
two main components. In both trial arms, rounds of
home-based counselling and HIV testing are repeated
every six months. All trial participants identified as
HIV-infected are then referred to a TasP trial clinic
located at less than 5 km from their homes. Each TasP
trial clinic is staffed by one nurse and one counsellor irre-
spective of population size. Busier clinics are occasionally
supported by additional staff depending on availability.
In the control clusters, HIV-infected adults are offered
ART according to South African guidelines which from
study inception to December 2014 was having one of
the following criteria: CD4 count ≤350 cells/mm3,
WHO stage 3 or 4 or pregnancy (National Department
of Health, Republic of South Africa, 2013). These criteria
were expanded in January 2015 to include those with
CD4≤ 500 cells/mm3, hepatitis B surface antigen posi-
tivity and HIV-positive partner in a serodiscordant
relationship regardless of CD4 count (National Depart-
ment of Health, Republic of South Africa, 2015). In the
intervention clusters, ART initiation is offered regardless
of CD4 count or clinical staging. HIV-care is also avail-
able in the public sector ART programme where HIV-
positive individuals can receive ART according to the
South African guidelines.
The trial was approved by the Biomedical Research
Ethics Committee (BREC) of the University of Kwa-
Zulu-Natal (BFC 104/11) and the Medicines Control
Council of South Africa.
Study population
This study used data collected up to 15 July 2015 in the
first 10 clusters including both arms of the trial (5 × 2).
The study population included HIV-positive individuals
who linked to care before 1 January 2015 (prior to
change in ART guidelines in South Africa), and were
not on ART at the baseline clinic visit but eligible for
ART initiation according to the trial protocol.
Variables
The event of interest is ART initiation defined as the first
time antiretroviral therapy was dispensed to the partici-
pant in a TasP clinic.
Explanatory variables used in the analysis included
data obtained through face-to-face questionnaires during
home-based visits as well as information collected at the
baseline clinic visit (Iwuji et al., 2013; Orne-Gliemann
et al., 2015). Information obtained during home visits
(Table 1) were: sex, age, education, occupational status,
household wealth, food insecurity, acceptability of
“immediate” ART, perception of stigma towards people
living with HIV and straight line distance between
homesteads and clinic. Information obtained at the base-
line clinic visit included: having a regular partner, HIV-
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Table 1. Factors associated with ART initiation in patients eligible to ART (according to trial protocol) not treated at baseline clinic visit, univariate and multivariate analyses (ANRS 12249
TasP trial, rural South Africa, N = 514).
N (%) at baseline
Univariate analyses Multivariate analyses
Main effect before
1 month
Effect change after
1 month
Main effect before
1 month
Effect change after
1 month
Main effect after
1 month
HR [95% CI] p-value HR [95% CI]
p-
value aHR [95% CI]
p-
value aHR [95% CI]
p-
value aHR [95% CI]
p-
value
Socio-demographic and economic characteristics (home-based questionnaires)
Gender
Male 152 (29.6) 1 1
Female 362 (70.4) 1.0 [0.8; 1.4] 0.819 1.0 [0.7; 1.5] 0.886
Age (years)
16–29 183 (35.6) 1 1 1 1 1
30–49 235 (45.7) 1.1 [0.8; 1.5] 0.445 1.1 [0.7; 1.7] 0.610 1.0 [0.7; 1.3] 0.967 1.3 [0.8; 2.0] 0.205 1.3 [0.9; 1.8] 0.101
+50 96 (18.7) 0.9 [0.6; 1.3] 0.448 1.4 [0.8; 2.4] 0.230 0.7 [0.5; 1.1] 0.153 2.0 [1.1; 3.6] 0.023 1.5 [1.0; 2.3] 0.074
Educational level
Primary and some secondary school 398 (77.4) 1 1
Completed secondary or higher 116 (22.6) 1.3 [1.0; 1.7] 0.069 0.7 [0.5; 1.1] 0.159
Having children
Yes 444 (86.4) 1 1
No 57 (11.1) 1.0 [0.7; 1.5] 0.970 0.7 [0.4; 1.3] 0.289
Missing 13 (2.5)
Occupational status
Employed 84 (16.3) 1 1
Student 27 (5.3) 1.2 [0.6; 2.1] 0.618 0.8 [0.3; 1.9] 0.545
Inactive (not employed and not student) 397 (77.2) 1.0 [0.7; 1.4] 0.935 0.9 [0.6; 1.5] 0.761
Missing 6 (1.2)
Household wealth assetsa
Low 186 (36.2) 1 1
Middle 221 (43.0) 0.9 [0.7; 1.2] 0.372 1.2 [0.8; 1.9] 0.344
High 104 (20.2) 0.7 [0.5; 1.1] 0.115 1.5 [0.9; 2.5] 0.119
Missing 3 (0.6)
Food insecurityb
Yes 317 (61.7) 1 1
No 183 (35.6) 1.1 [0.8; 1.4] 0.600 0.8 [0.5; 1.1] 0.183
Missing 14 (2.7)
Distance from home to the closest TasP clinic within the same cluster
≤1 km 214 (41.6) 1 1
>1 km 300 (58.4) 1.5 [1.1; 1.9] 0.005 0.6 [0.4; 0.9] 0.014
Stigma and treatment perception variables (home-based questionnaires)
Thinking that people avoid HIV+ individuals
Agree 184 (35.8) 1 1
Disagree + Don’t know 326 (63.4) 1.1 [0.8; 1.4] 0.476 1.0 [0.7; 1.5] 0.926
Missing 4 (0.8)
Thinking that people don’t blame HIV+ individuals
Agree 265 (51.6) 1 1
Disagree + Don’t know 247 (48.1) 0.9 [0.7; 1.1] 0.336 1.1 [0.8; 1.6] 0.551
(Continued )
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Table 1. Continued.
N (%) at baseline
Univariate analyses Multivariate analyses
Main effect before
1 month
Effect change after
1 month
Main effect before
1 month
Effect change after
1 month
Main effect after
1 month
HR [95% CI] p-value HR [95% CI]
p-
value aHR [95% CI]
p-
value aHR [95% CI]
p-
value aHR [95% CI]
p-
value
Missing 2 (0.4)
Would accept to take ART immediately if diagnosed HIV+? (Acceptability of “immediate” ART)
Agree 484 (94.2) 1 1
Disagree + Don’t know 24 (4.7) 0.6 [0.3; 1.1] 0.107 1.6 [0.7; 4.0] 0.285
Missing 6 (1.2)
Psychosocial variables (Clinic-based questionnaire)
Having a regular partner
Yes 397 (77.2) 1 1 1 1 1
No 108 (21.0) 1.3 [1.0; 1.8] 0.076 0.6 [0.4; 0.9] 0.021 1.3 [0.9; 1.8] 0.090 0.4 [0.2; 0.7] 0.001 0.5 [0.4; 0.8] 0.003
Missing 9 (1.8)
Disclosure of HIV status to partner
Yes 278 (54.1) 1 1
No 111 (21.6) 1.3 [0.9; 1.7] 0.147 0.6 [0.4; 1.0] 0.037
No partner 108 (21.0) 1.4 [1.0; 1.9] 0.040 0.5 [0.3; 0.8] 0.006
Missing 17 (3.3)
Score of HIV disclosure (no of persons)
None 77 (15.0) 1 1
One 152 (29.6) 1.0 [0.7; 1.5] 0.922 1.0 [0.6; 1.9] 0.877
Two 115 (22.4) 0.9 [0.6; 1.3] 0.506 1.2 [0.6; 2.2] 0.634
Three or more 166 (32.3) 0.9 [0.6; 1.4] 0.738 1.3 [0.7; 2.3] 0.437
Missing 4 (0.8)
Social support
Yes 389 (75.7) 1 1
No 111 (21.6) 1.1 [0.8; 1.5] 0.448 0.6 [0.4; 0.9] 0.018
Missing 14 (2.7)
Psychological distress (PHQ4 score)
None 357 (69.5) 1 1
Mild 132 (25.7) 1.0 [0.7; 1.3] 0.871 1.4 [0.9; 2.2] 0.091
Moderate or severe 13 (2.5) 0.9 [0.3; 2.3] 0.775 1.3 [0.3; 4.9] 0.704
Missing 12 (2.3)
Linkage to care history and clinical variables (Clinic-based questionnaire)
Time between referral and baseline
<3 months 375 (73.0) 1 1
≥3 months 139 (27.0) 0.9 [0.7; 1.2] 0.356 1.1 [0.7; 1.7] 0.563
Newly diagnosed at referral
No 426 (82.9) 1
Yes 88 (17.1) 1.0 [0.7; 1.4] 0.951 0.8 [0.5; 1.4] 0.451
ART-naïve at baseline
No 85 (16.5) 1
Yes 419 (81.5) 1.0 [0.7; 1.4] 1.0 0.8 [0.5; 1.4] 0.493
Missing 10 (2.0)
Eligibility criteria and CD4 count (cells/mm3)
CD4≤ 100 45 (8.8) 1 1 1 1 1
CD4 between ]100–200] 84 (16.3) 0.6 [0.4; 1.0] 0.037 2.2 [0.9; 5.3] 0.087 0.6 [0.4; 1.0] 0.055 2.7 [1.1; 6.9] 0.037 1.7 [0.8; 3.9] 0.188
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status disclosure, social support, psychological distress
[Patient Health Questionnaire-4 score (Kroenke, Spitzer,
Williams, & Löwe, 2009; Löwe et al., 2010)], time
between referral and baseline clinic visit, being newly
diagnosed at referral, being ART-naïve and CD4 count
at baseline combined with other eligibility criteria
(WHO stage 3 or 4 and pregnancy for women). Clusters
have been grouped to construct a three-category variable:
(i) clusters A–D, opened in 2012, stratified as having
lower HIV prevalence (21.7–24.5%), relatively high
staff–patient ratios (2.1–3.1 per 100 patients) and fixed
clinics; (ii) clusters E and F, opened in 2013, having com-
parable HIV prevalence (21.1–22.5%), high staff–patient
ratios (2.7–5.7 per 100 patients) and mobile clinics
opened during week days only; (iii) clusters G–J, opened
in 2013, having higher HIV prevalence (32.5–39.8%),
low staff–patient ratios (0.6–1.3 per 100 patients) and
mobile clinics opened weekdays and Saturdays.
Statistical analysis
Follow-up period was defined as the period between
baseline clinic visit and ART initiation, with right-cen-
soring at last follow-up clinic visit of each patient. The
follow-up time for patients having only the baseline
visit was defined as one day (Howards, Hertz-Picciotto,
& Poole, 2007).
The association between the explanatory variables and
ART initiation was assessed using an extension of the Cox
proportional hazard (PH) model which includes an inter-
action with a step function that takes into account that
covariate effects may change over time. Two different
effects were tested: a “main effect” corresponding to the
hazard ratio (HR) over the first month of follow-up,
and a change in the main effect after 30 days (“effect
change after one month”). The 30-day threshold was
assessed by plotting the Kaplan–Meier survival curves
(i.e., the cumulative probability of not being ART treated)
according to the different categories of the covariates. The
introduction of an interaction with time through a step
function was also justified by the results of the test of
PH assumption, based on the rescaled Schoenfeld
residuals (Grambsch & Therneau, 1994) performed in
the standard Cox model which showed that the PH
assumption was violated for some covariates.
Potential explanatory variables having a p-value <0.25
for the main effect or for an effect change, for at least one
category (Wald test) in the univariate analyses, were con-
sidered eligible for inclusion in the multivariate analysis.
A backward stepwise procedure was then used to select
variables in the final multivariate model with a p-value
≤0.05 (Wald test). A main effect after one month of fol-
low-up was also computed for the multivariate model,C
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corresponding to the product of the main effect and the
effect change after one month. A global Chi-square test
was performed to test the Cox specification using the
interaction with time vs. the standard Cox specification
in the final multivariate model.
Stata/SE 12.1 for Windows software (StataCorp, 2011)
was used for all analyses.
Results
Study population
The study population included 514 individuals (Figure 1).
Baseline characteristics are presented in Table 1: 70.4%
were women, 35.6% less than 30 years old. Most of
them had a poor socio-economic status: only 22.6% com-
pleted secondary or higher education, 77.2% reported
being inactive (not employed and not student) and
61.7% declared food insecurity (not having enough food
for adult household members). Most reported having a
regular partner (77.2%), while 15.0% had not disclosed
their HIV status to anyone and nearly a quarter reported
no social support (21.6%). Most of the patients (73.0%)
entered into care within three months of referral. A
small minority (8.8%) had less than 100 CD4/mm3 at
baseline and 45.3% more than 350 CD4/mm3.
Descriptive analysis of ART initiation
The 514 study patients had a median [interquartile range
(IQR)] duration of follow-up of 1.08 [0.69; 2.07] months
until ART initiation or last visit, representing 1206.4 per-
son-months. Among them, 451 (87.7%) initiated ART
during the follow-up period. Table 2 presents the rates
(cumulative probabilities) of ART initiation by cluster
and overall, at one month (M1), three months (M3)
and six months (M6) from the baseline visit. The overall
rate of ART initiation at M1 was 49.5%, increasing to
82.2% and 88.7% at M3 and M6, respectively. We also
observed a large variability across clusters, especially at
M1, with rates varying between 38.4% and 83.3%.
Figure 2 and Table 3 show, respectively, the cumulat-
ive probability of ART initiation, estimated using
Kaplan–Meier curves, and the corresponding estimated
rates at M1, M3 and M6 (both overall and according
to CD4 count and other eligibility criteria). Rates of
ART initiation at M6 were quite similar and ranged
from 85.3% to 96.1% (except for the specific subgroup
with CD4≥ 350 cells/mm3 and WHO stage 3/4 or preg-
nancy who had a rate of ART initiation of 60.5% at M6)
(Table 3). However, rates of ART initiation at M1 varied
substantially according to CD4 and other eligibility cri-
teria; ranging from 55.2% to 71.8% in those with
CD4≤ 350 cells/mm3 compared to 30.7% in the category
WHO stage 3/4 or pregnancy and 36.9% in the category
without WHO stage 3/4 or pregnancy, in those with
CD4 > 350 cells/mm3.
Factors associated with ART initiation
Table 1 presents factors associated with ART initiation in
univariate and multivariate analyses.
Explanatory variables included in the multivariate
analysis included age, educational level, household
assets, food insecurity, agreeing to start ART immedi-
ately if diagnosed HIV-positive, disclosure of HIV status
to partner, social support, psychological distress score,
distance to clinic, CD4 count combined with WHO
stage 3/4 and pregnancy for women and cluster profile.
The final multivariate model confirmed most of the
statistically significant associations found in univariate
analyses. First, all categories of eligible patients according
to national guidelines (with CD4 between [100–200],
[200–350] and CD4 > 350 for individuals in WHO
stage 3/4 or pregnancy) experienced lower ART within
M1 compared to those with CD4≤ 100 cells/mm3, with
a gradient according to CD4 categories (main HR [95%
CI]= 0.6 [0.4; 1.0], 0.5 [0.3; 0.8] and 0.2 [0.1; 0.4],
respectively). This main effect was no longer statistically
significant after the first month (p = 0.188, 0.055 and
0.098, respectively). Similarly, patients with CD4 count
>350 cells/mm3 but without WHO stage 3/4 or preg-
nancy were less likely to initiate ART within M1 com-
pared with those with CD4 count ≤100 cells/mm3 (HR
[95% CI] = 0.3 [0.2; 0.4]) but this association was no
longer significant beyond M1 (p = .495). Second, report-
ing a regular partner was not significantly associated
with ART initiation within M1 in the multivariate analy-
sis (p = .090), but the effect change after one month was
significant, suggesting that patients without a regular
partner were less likely to initiate ART after M1 (change
HR [95% CI] = 0.4 [0.2; 0.7], main HR after M1 [95%
CI] = 0.5 [0.4; 0.8]). Moreover, individuals in Clusters
G–J were significantly less likely to initiate ART within
the first month (HR [95% CI] = 0.4 [0.3; 0.6]), compared
to those in Clusters A–D. However, a significant effect
change after M1 (change HR [95% CI] = 1.7 [1.0; 2.9])
compensates the main effect to give a non-significant
main effect after M1 (p = .245). Finally, despite no sig-
nificant association between age and ART initiation in
univariate analysis, and also no significant association
over the first month of follow-up in multivariate analysis,
we observed a significant effect change after M1 for the
patients older than 50 years compared with those aged
16–29 years (change HR [95% CI] = 2.0 [1.1; 3.6] and
main HR after M1 [95% CI] = 1.5 [1.0; 2.3]).
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The result of the global Chi-square test (p < 10−3)
confirmed Cox specification using the interaction with
time vs. the standard Cox specification in the final multi-
variate model.
Discussion
This study presents early findings on ART uptake and
factors associated with ART initiation among HIV-posi-
tive individuals who had linked to care in the trial clinics
and were eligible for ART at their first clinic visit within
the setting of an ongoing UTT cluster randomized trial
in rural KwaZulu-Natal, South Africa.
Our results show that ART uptake was high, with
more than four of five individuals initiating ART within
the first three months of entering care, a promising
observation. Furthermore, the rates of those with CD4
> 350 cells/mm3 and without WHO stage 3/4 or
pregnancy who initiated ART were as high as 79.8% at
month 3 and 85.3% at M6. However, the concept of
“immediate ART” needs to be nuanced. Even in the con-
text of overall high ART uptake, only half the individuals
initiated ART within one month with our findings
suggesting a more rapid initiation in sicker patients.
Furthermore, participants’ clinical characteristics and
cluster of residence were dominant in the first month
amongst the factors associated with ART initiation,
while the additional effects of socio-demographic vari-
ables were observed beyond the first month. Individuals
with higher CD4 counts at baseline were indeed less likely
to initiate ART compared to those with CD4≤ 100 cells/
mm3 within the first month of entering care. However,
this difference was not observed beyond the first month.
Previous studies conducted at a time when ART prescrip-
tion was still restricted according to clinical and immuno-
logical criteria have suggested that individuals with
Figure 1. Flow chart of the study (ANRS 12249 TasP trial, rural South Africa).
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asymptomatic HIV disease or who do not feel sick as a
result of their HIV infection are less aware of the need
to initiate ART (Fox et al., 2010; Plazy, Dray-Spira,
Orne-Gliemann, Dabis, & Newell, 2014). A study from
the same district showed that between 2007 and 2011,
only 65.5% of ART-eligible individuals initiated ART;
with ART initiation being more likely in females, those
≥25 years and those with low CD4 counts (Plazy et al.,
2014). However, an alternative explanation for the lack
of a difference in ART initiation by CD4 count category
after the first month could be that the initial difference
observed was driven by healthcare professionals’
(HCPs) practices and may reflect the emergency per-
ceived by physicians to start ART as soon as possible in
individuals with CD4 count≤100 cells/mm3. Conversely,
for patients with CD4 count >350 cells/mm3, informal
discussions with local HCPs suggest that more time is
taken both to assess the potential risks of side effects
and to prepare patients to initiate lifelong ART.
In addition, we observed a significant cluster effect on
ART initiation with individuals from higher prevalence
clusters who attend clinics with low staff–patient ratio
being less likely to initiate ART within the first month
compared to their counterparts with a higher ratio.
This difference is further buttressed by the descriptive
analysis showing large variations in ART initiation
rates between clusters. As previously, the difference
observed in ART initiation rates between clusters disap-
peared after the first month. This suggests that the initial
delay observed was not due to patients with higher CD4
counts being reluctant to start ART but was rather due to
clinics’ characteristics such as staffing capacity and work-
load, and potentially due to triage according to CD4 cell
counts by HCP.
South Africa will likely implement soon the 2015
WHO guidelines recommending universal ART, that
is, regardless of CD4 count (WHO, 2015). This will
lead to large numbers of individuals in care becoming eli-
gible for ART. It is conceivable that after many years of
guidelines for ART initiation emphasizing the need to
focus on HIV-positive individuals with lower CD4
counts who are at increased risk of opportunistic dis-
eases, HCPs may continue to prioritize those with
lower CD4 counts over those with higher CD4 counts.
Individual benefits of ART would thus remain high
[although recent clinical trials indicate clear additional
benefits of early ART initiation (INSIGHT START
Study Group et al., 2015; TEMPRANO ANRS 12136
Study Group et al., 2015] but the public health impact
of preventing transmission may not be optimal unless
the health system is strengthened to deal with the chal-
lenges of high patient flow. Innovative approaches to
decongest the health system would be required such asT
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adherence clubs, support by peers, three-monthly drug
pick-ups and less frequent clinic attendance for stable
patients (Duncombe et al., 2015; Ellman, 2015; Grims-
rud, Lesosky, Kalombo, Bekker, & Myer, 2016; Khabala
et al., 2015). Their combination will be necessary to cre-
ate additional capacity in clinics to see most HIV-posi-
tive individuals initiating ART rapidly.
Regarding socio-demographic characteristics, we
found that having a regular partner was associated
with higher likelihood of ART initiation after one
month despite no significant association during the
first month. This variable may capture the psychosocial
benefit of being in a stable relationship and of mutual
support. This association has also been shown in adher-
ence behaviour studies in Cameroon (Boyer et al., 2011).
Furthermore, while some studies showed that women
were more likely to initiate ART that men (Mugglin
et al., 2012; Plazy et al., 2014), we did not find any signifi-
cant association between ART initiation and gender.
This result is however consistent with several recent
studies conducted in Nigeria, Malawi and Uganda
(Aliyu et al., 2014; Feldacker, Johnson, Hosseinipour,
Phiri, & Tweya, 2012; Katz et al., 2011; MacPherson
et al., 2012). In addition, two studies carried out within
our trial population showed no significant association
between linkage to care and gender (Plazy et al., 2015)
but a significant association between HIV testing and
gender with a lower acceptability of home-based HIV
testing among men (Larmarange et al., 2014).
Our study has some limitations. First, our sample size
may have limited the statistical power to detect some
effects. Second, recent changes in South Africa regarding
the adoption in January 2015 of the 2013WHOguidelines
as well as the expected adoption in the near future of the
2015 WHO guidelines may have some implications for
the study’s results, analysis and interpretation. As patients
with CD4 count >350 cells/mm3 will then become eligible
for ART according to national guidelines, it is possible
that the delay observed during the first month of care in
ART initiation amongst individuals with higher CD4
counts may not be replicated. However, considering
that large numbers of patients will become immediately
eligible to initiate ART with the universal treatment
guidelines, coupled with existing health-care system con-
straints in terms of human resources (Coovadia, Jewkes,
Barron, Sanders, & McIntyre, 2009; Health Systems
Trust, 2008), the delay observed in our study may be
accentuated, at least at the beginning of the implemen-
tation of the new guidelines.
Our results also suggest that in the context of UTT
where all HIV-positive individuals are eligible for ART,
and where the concept of “pre-ART” care will gradually
disappear, ART initiation could be seen as one of the last
steps of a shortened entry into the care process starting
with HIV diagnosis. Hence, it could be relevant to change
our perspective from considering “linkage to care” and
“ART initiation” as two separate processes to a global “link-
age to ART” perspective, from the first “90” to the second
“90” to echo UNAID’s 90–90–90 target (UNAIDS, 2014).
To conclude, our results can help inform policy on the
challenges related to ART initiation in the setting of any
UTT strategy. These early findings suggest a good
acceptability of ART within a UTT setting, even
among individuals with high CD4 counts, but revealed
that ART initiation among sicker patients could remain
prioritized over those with higher CD4 counts due to
staffing capacity as well as HCPs’ practices that will prob-
ably take time to change.
Figure 2. (a) Overall cumulative probability of not being ART
treated among ART-eligible patients (according to trial protocol)
at baseline clinic visit (Kaplan–Meier curves, ANRS 12249 TasP
trial, rural South Africa, N = 514). (b) Cumulative probability of
not being ART treated according to eligibility criteria among
ART-eligible patients (according to trial protocol) at baseline
clinic visit (Kaplan–Meier curves, ANRS 12249 TasP trial, rural
South Africa, N = 514).
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